The estimated Net Worth of Frederick W Ahlholm is at least $1.18 Milion dollars as of 28 April 2023. Mr. Ahlholm owns over 3,580 units of Minerva Neurosciences Inc stock worth over $46,773 and over the last 10 years he sold NERV stock worth over $353,793. In addition, he makes $784,339 as Senior Vice President a Chief Accounting Officer at Minerva Neurosciences Inc.
Frederick has made over 7 trades of the Minerva Neurosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 3,580 units of NERV stock worth $16,038 on 28 April 2023.
The largest trade he's ever made was exercising 21,631 units of Minerva Neurosciences Inc stock on 1 June 2017 worth over $108,804. On average, Frederick trades about 3,528 units every 161 days since 2014. As of 28 April 2023 he still owns at least 17,518 units of Minerva Neurosciences Inc stock.
You can see the complete history of Mr. Ahlholm stock trades at the bottom of the page.
Frederick Ahlholm CPA serves as Senior Vice President, Chief Accounting Officer of the Company. He has provided services to us since January 2014, first as a consultant and then as an employee beginning in June 2014. Mr. Ahlholm was named our Vice President and Chief Accounting Officer in July 2014 and was named Senior Vice President in May 2015. Prior to joining us, from 2010 to 2013, Mr. Ahlholm served as Vice President of Finance and also as Chief Accounting Officer for Amarin Corporation, a commercial biopharmaceutical company. Mr. Ahlholm has over 15 years of experience leading the finance organization at publicly-traded biotech companies, is a CPA and earned his BA in Business Administration at the University of Notre Dame.
As the Senior Vice President a Chief Accounting Officer of Minerva Neurosciences Inc, the total compensation of Frederick Ahlholm at Minerva Neurosciences Inc is $784,339. There are 5 executives at Minerva Neurosciences Inc getting paid more, with Michael Davidson having the highest compensation of $2,842,430.
Frederick Ahlholm is 54, he's been the Senior Vice President a Chief Accounting Officer of Minerva Neurosciences Inc since 2015. There are 17 older and 3 younger executives at Minerva Neurosciences Inc. The oldest executive at Minerva Neurosciences Inc is David Kupfer, 79, who is the Independent Director.
Frederick's mailing address filed with the SEC is C/O MINERVA NEUROSCIENCES, INC., 1500 DISTRICT AVENUE, BURLINGTON, MA, 01803.
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over $49,043,620 worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth $47,876,311 . The most active insiders traders include & Johnson Johnson & Johnson..., Venture Associates Iii Ltd ... a Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $556,476. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth $105,193.
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include: